Loading
A phase 1/2 trial of Alectinib in brain and spinal cord tumours, run by Hoffmann-La Roche, active and no longer recruiting.
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors is a phase 1/2 interventional study registered as NCT04774718 by Hoffmann-La Roche, with 42 participants enrolled, started 2021-09-14 and due to reach its primary completion in 2032-02-28. Interventions recorded: Alectinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Flatiron Health (Roche), Brain and spinal cord tumours (all types), Small-molecule kinase inhibitors and the tag pipeline.
Shares Alectinib, Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche) and the tag pipeline.
Shares Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/